ANS 014004
Alternative Names: ANS-01; ANS-014004Latest Information Update: 10 Oct 2024
At a glance
- Originator Avistone Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- Preclinical Gastric cancer; Non-small cell lung cancer
Most Recent Events
- 04 Oct 2024 ANS 014004 cleared to proceed with enrollment of patients in Canada
- 20 Apr 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy) in USA (PO) (NCT06307795)
- 19 Mar 2024 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Inoperable/Unresectable) in China (PO) (NCT06328439)